$29.71
-0.79-2.59%
At close: -
$29.71
0.000.00%
After Hours: 4:36 PM EDT
Comments
Loading...
Veracyte Analyst Ratings and Price Targets | NASDAQ:VCYT | Benzinga
Veracyte Inc has a consensus price target of $41.1 based on the ratings of 11 analysts. The high is $51 issued by Needham on February 25, 2025. The low is $28 issued by Morgan Stanley on November 18, 2024. The 3 most-recent analyst ratings were released by Guggenheim, Stephens & Co., and Craig-Hallum on April 9, 2025, March 26, 2025, and March 20, 2025, respectively. With an average price target of $42.33 between Guggenheim, Stephens & Co., and Craig-Hallum, there's an implied 42.49% upside for Veracyte Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
Stephens & Co.
Craig-Hallum
UBS
Needham
1calculated from analyst ratings
Analyst Ratings for Veracyte
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/09/2025 | Buy Now | 24.54% | Guggenheim | Subbu Nambi44% | $45 → $37 | Maintains | Buy | Get Alert |
| 03/26/2025 | Buy Now | 51.46% | Stephens & Co. | Mason Carrico39% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2025 | Buy Now | 51.46% | Craig-Hallum | John Wilkin13% | → $45 | Initiates | → Buy | Get Alert |
| 02/25/2025 | Buy Now | 64.93% | UBS | Lu Li14% | $46 → $49 | Maintains | Buy | Get Alert |
| 02/25/2025 | Buy Now | 51.46% | Guggenheim | Subbu Nambi44% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 02/25/2025 | Buy Now | 71.66% | Needham | Mike Matson56% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2025 | Buy Now | 71.66% | Needham | Mike Matson56% | $44 → $51 | Maintains | Buy | Get Alert |
| 12/05/2024 | Buy Now | 24.54% | Goldman Sachs | Matthew Sykes66% | $38 → $37 | Downgrade | Buy → Neutral | Get Alert |
| 11/18/2024 | Buy Now | -5.76% | Morgan Stanley | Tejas Savant50% | $26 → $28 | Maintains | Underweight | Get Alert |
| 11/08/2024 | Buy Now | 48.1% | Scotiabank | Sung Ji Nam45% | $40 → $44 | Maintains | Sector Outperform | Get Alert |
| 11/07/2024 | Buy Now | 27.9% | Goldman Sachs | Matthew Sykes66% | $34 → $38 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 54.83% | UBS | Lu Li14% | $43 → $46 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 48.1% | Needham | Mike Matson56% | $37 → $44 | Maintains | Buy | Get Alert |
| 10/17/2024 | Buy Now | 34.63% | Leerink Partners | Puneet Souda57% | $35 → $40 | Maintains | Outperform | Get Alert |
| 10/16/2024 | Buy Now | 44.73% | UBS | Lu Li14% | → $43 | Initiates | → Buy | Get Alert |
| 10/10/2024 | Buy Now | 34.63% | Guggenheim | Subbu Nambi44% | → $40 | Initiates | → Buy | Get Alert |
| 08/28/2024 | Buy Now | 24.54% | Needham | Mike Matson56% | $31 → $37 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | -12.49% | Morgan Stanley | Tejas Savant50% | $21 → $26 | Maintains | Underweight | Get Alert |
| 08/07/2024 | Buy Now | 4.34% | Needham | Mike Matson56% | $27 → $31 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | -9.12% | Needham | Mike Matson56% | $33 → $27 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | -5.76% | Goldman Sachs | Matthew Sykes66% | $32 → $28 | Maintains | Buy | Get Alert |
| 02/26/2024 | Buy Now | -29.32% | Morgan Stanley | Tejas Savant50% | $22 → $21 | Maintains | Underweight | Get Alert |
| 02/23/2024 | Buy Now | 11.07% | Needham | Mike Matson56% | $30 → $33 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | -25.95% | Morgan Stanley | Tejas Savant50% | $23 → $22 | Maintains | Underweight | Get Alert |
| 11/08/2023 | Buy Now | 0.98% | Needham | Mike Matson56% | $35 → $30 | Maintains | Buy | Get Alert |
| 10/23/2023 | Buy Now | 7.71% | Goldman Sachs | Matthew Sykes66% | $37 → $32 | Maintains | Buy | Get Alert |
| 10/20/2023 | Buy Now | 7.71% | Goldman Sachs | Matthew Sykes66% | $37 → $32 | Maintains | Buy | Get Alert |
| 10/10/2023 | Buy Now | 14.44% | Stephens & Co. | Mason Carrico39% | → $34 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | -22.58% | Morgan Stanley | Tejas Savant50% | $22 → $23 | Maintains | Underweight | Get Alert |
| 08/09/2023 | Buy Now | 17.81% | Needham | Mike Matson56% | $34 → $35 | Maintains | Buy | Get Alert |
| 05/08/2023 | Buy Now | 0.98% | Stephens & Co. | Mason Carrico39% | → $30 | Reiterates | → Overweight | Get Alert |
| 02/23/2023 | Buy Now | 14.44% | Needham | Mike Matson56% | $33 → $34 | Maintains | Buy | Get Alert |
| 01/18/2023 | Buy Now | — | Raymond James | Andrew Cooper55% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 01/05/2023 | Buy Now | 11.07% | Scotiabank | Sung Ji Nam45% | → $33 | Initiates | → Sector Outperform | Get Alert |
| 11/04/2022 | Buy Now | -25.95% | Morgan Stanley | Tejas Savant50% | $23 → $22 | Maintains | Underweight | Get Alert |
| 11/04/2022 | Buy Now | -9.12% | Raymond James | Andrew Cooper55% | $31 → $27 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 11.07% | Needham | Mike Matson56% | $31 → $33 | Maintains | Buy | Get Alert |
| 11/03/2022 | Buy Now | 17.81% | SVB Leerink | Puneet Souda57% | $30 → $35 | Maintains | Outperform | Get Alert |
| 08/04/2022 | Buy Now | 4.34% | Raymond James | Andrew Cooper55% | $30 → $31 | Maintains | Outperform | Get Alert |
| 08/03/2022 | Buy Now | 4.34% | Needham | Mike Matson56% | $26 → $31 | Maintains | Buy | Get Alert |
| 05/05/2022 | Buy Now | 0.98% | Stephens & Co. | Mason Carrico39% | $44 → $30 | Maintains | Overweight | Get Alert |
| 05/04/2022 | Buy Now | -22.58% | Morgan Stanley | Tejas Savant50% | $25 → $23 | Maintains | Underweight | Get Alert |
| 05/04/2022 | Buy Now | 0.98% | Raymond James | Andrew Cooper55% | $34 → $30 | Maintains | Outperform | Get Alert |
| 05/04/2022 | Buy Now | -12.49% | Needham | Mike Matson56% | $31 → $26 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Veracyte (VCYT) stock?
The latest price target for Veracyte (NASDAQ:VCYT) was reported by Guggenheim on April 9, 2025. The analyst firm set a price target for $37.00 expecting VCYT to rise to within 12 months (a possible 24.54% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Veracyte (VCYT)?
The latest analyst rating for Veracyte (NASDAQ:VCYT) was provided by Guggenheim, and Veracyte maintained their buy rating.
When was the last upgrade for Veracyte (VCYT)?
There is no last upgrade for Veracyte
When was the last downgrade for Veracyte (VCYT)?
The last downgrade for Veracyte Inc happened on December 5, 2024 when Goldman Sachs changed their price target from $38 to $37 for Veracyte Inc.
When is the next analyst rating going to be posted or updated for Veracyte (VCYT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Veracyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Veracyte was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.
Is the Analyst Rating Veracyte (VCYT) correct?
While ratings are subjective and will change, the latest Veracyte (VCYT) rating was a maintained with a price target of $45.00 to $37.00. The current price Veracyte (VCYT) is trading at is $29.71, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
